Revance Therapeutics (RVNC) Competitors

72.8% of Harrow shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Harrow has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

In the previous week, Harrow had 3 more articles in the media than Revance Therapeutics. MarketBeat recorded 3 mentions for Harrow and 0 mentions for Revance Therapeutics. Harrow's average media sentiment score of 0.11 beat Revance Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the media.

Harrow has higher revenue and earnings than Revance Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Harrow has a net margin of -1.89% compared to Revance Therapeutics' net margin of -74.67%. Harrow's return on equity of 36.51% beat Revance Therapeutics' return on equity.

Harrow currently has a consensus price target of $69.86, suggesting a potential upside of 82.73%. Given Harrow's stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than Revance Therapeutics.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 10.5% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Revance Therapeutics. MarketBeat recorded 2 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Revance Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.84 beat Revance Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Revance Therapeutics. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $43.40, suggesting a potential upside of 79.64%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Revance Therapeutics.

In the previous week, Ardelyx had 17 more articles in the media than Revance Therapeutics. MarketBeat recorded 17 mentions for Ardelyx and 0 mentions for Revance Therapeutics. Ardelyx's average media sentiment score of 0.06 beat Revance Therapeutics' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Ardelyx has higher revenue and earnings than Revance Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Revance Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ardelyx has a net margin of -13.58% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.

Ardelyx has a consensus price target of $15.70, indicating a potential upside of 131.56%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Revance Therapeutics.

In the previous week, Immunocore had 8 more articles in the media than Revance Therapeutics. MarketBeat recorded 8 mentions for Immunocore and 0 mentions for Revance Therapeutics. Immunocore's average media sentiment score of 0.62 beat Revance Therapeutics' score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Immunocore has higher revenue and earnings than Revance Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Revance Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunocore has a net margin of -6.68% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Immunocore's return on equity.

Immunocore has a consensus price target of $57.75, indicating a potential upside of 95.23%. Given Immunocore's stronger consensus rating and higher possible upside, analysts plainly believe Immunocore is more favorable than Revance Therapeutics.